4.7 Article

Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies

期刊

SCIENTIFIC REPORTS
卷 10, 期 1, 页码 -

出版社

NATURE RESEARCH
DOI: 10.1038/s41598-020-77210-y

关键词

-

资金

  1. Horngren Family Alzheimer's Research Fund
  2. Jean Perkins Foundation
  3. Taube Philanthropies
  4. Koret Foundation
  5. General Alzheimer's Research Donor Fund
  6. Buena Thomas AD Research Fund

向作者/读者索取更多资源

Longitudinal preclinical and clinical studies suggest that A beta drives neurite and synapse degeneration through an array of tau-dependent and independent mechanisms. The intracellular signaling networks regulated by the p75 neurotrophin receptor (p75(NTR)) substantially overlap with those linked to A beta and to tau. Here we examine the hypothesis that modulation of p75(NTR) will suppress the generation of multiple potentially pathogenic tau species and related signaling to protect dendritic spines and processes from A beta -induced injury. In neurons exposed to oligomeric A beta in vitro and APP mutant mouse models, modulation of p75(NTR) signaling using the small-molecule LM11A-31 was found to inhibit A beta -associated degeneration of neurites and spines; and tau phosphorylation, cleavage, oligomerization and missorting. In line with these effects on tau, LM11A-31 inhibited excess activation of Fyn kinase and its targets, tau and NMDA-NR2B, and decreased Rho kinase signaling changes and downstream aberrant cofilin phosphorylation. In vitro studies with pseudohyperphosphorylated tau and constitutively active RhoA revealed that LM11A-31 likely acts principally upstream of tau phosphorylation, and has effects preventing spine loss both up and downstream of RhoA activation. These findings support the hypothesis that modulation of p75(NTR) signaling inhibits a broad spectrum of A beta -triggered, tau-related molecular pathology thereby contributing to synaptic resilience.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据